MaSTherCell brings ‘large-scale’ advanced therapeutics manufacturing to Europe

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Ismagilov)
(Image: Getty/Ismagilov)
The CDMO leases a facility in Belgium to manufacture cell and gene therapies at a large-scale, in a move the company claims is a first in Europe.

MaSTherCell, a dedicated cell and gene therapy contract development and manufacturing organisation (CDMO), has leased a 61,354ft facility in Gosselies Biopark, Brussels.

The site will be used for the production of late-stage clinical and commercial cell and gene therapy products, with the site expected to be operational in early 2021.

In addition to the scale of the facility, which will create several hundred jobs, MaSTherCell noted that it will also hold Industry 4.0 technology – such as “software integration, intelligent equipment, and integrated processes.”

CEO of MaSTherCell, Denis Bedoret, stated that the site will play a role in “solving the current lack of commercial manufacturing capabilities in Europe.”

With a number of cell and gene therapies currently in the pipeline​, preparing for the commercial assets that will emerge by increasing capacity is in-step with other manufacturing organisations​ and companies​ across Europe.

“With this new site, we aim to be the first CDMO in Europe to have a dedicated area for large-scale commercial manufacturing,”​ Bedoret added.

As a result, MaSTherCell will refocus its existing infrastructure on earlier stage clinical production. The choice to lease a facility in Gosselies Biopark adds to the capabilities the company already has in the location, which held a facility in the location when Orgenesis bought MaSTherCell in 2015​.

“It was natural for us to set up this state-of-the-art plant in the Gosselies Biopark. Not only will we remain close to our current site and centre of excellence, but also because operating in this world-leading biotechnology cluster will enable us to benefit from a first-class environment in terms of skills, people and know-how,”​ explained Eric Mathieu, COO of MaSTherCell.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars